Clinical Trial Update: Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 safety trial of adjuvant gemcitabine after laparoscopic distal pancreatectomy for pancreatic adenocarcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Pancreatic Neoplasms | Phase 2 | Status: WITHDRAWN